Latest news and press releases about Innate Pharma S.A. (IPHA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections.
Price
| Price | $2.01 |
| Market Cap | $189M |
| Exchange | NASDAQ |
| Country | FR |
Valuation Ratios
| Price / Book | -6.93 |
| EV / EBITDA | -2.50 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 593.93% |
| Return on Invested Capital | -155.52% |
| Return on Assets | -78.41% |
| Gross Margin | 100.00% |
| Operating Margin | -2058.02% |
| Net Margin | -1764.51% |
Related companies: APLT · CGEN · CRBP · CRDF · CYBN · ELTX · MIST
Explore sector: Healthcare · Biotechnology
More sections of IPHA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks